FibroGen Inc (NASDAQ:FGEN) – Investment analysts at Svb Leerink dropped their FY2019 earnings estimates for shares of FibroGen in a report released on Wednesday, February 12th. Svb Leerink analyst G. Porges now expects that the biopharmaceutical company will earn ($0.64) per share for the year, down from their prior forecast of ($0.06). Svb Leerink also issued estimates for FibroGen’s Q4 2019 earnings at ($0.87) EPS, Q1 2020 earnings at ($0.17) EPS, Q3 2020 earnings at ($0.71) EPS, Q4 2020 earnings at ($0.35) EPS, FY2020 earnings at $2.25 EPS, FY2021 earnings at ($0.23) EPS and FY2022 earnings at $2.33 EPS.
Several other research firms have also recently issued reports on FGEN. BidaskClub raised FibroGen from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. Mizuho restated a “buy” rating and set a $72.00 price target on shares of FibroGen in a research report on Thursday. ValuEngine upgraded FibroGen from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Finally, Zacks Investment Research lowered FibroGen from a “strong-buy” rating to a “hold” rating in a research report on Friday. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $51.25.
NASDAQ:FGEN opened at $45.58 on Friday. FibroGen has a one year low of $32.33 and a one year high of $61.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 8.95 and a current ratio of 9.01. The stock has a market cap of $3.86 billion, a PE ratio of 116.87 and a beta of 1.95. The stock has a 50 day moving average price of $43.35 and a 200 day moving average price of $42.25.
A number of large investors have recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in FibroGen by 36.1% in the third quarter. Barclays PLC now owns 153,930 shares of the biopharmaceutical company’s stock valued at $5,692,000 after buying an additional 40,798 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in FibroGen in the fourth quarter valued at $3,091,000. Woodstock Corp raised its stake in FibroGen by 119.8% in the fourth quarter. Woodstock Corp now owns 22,020 shares of the biopharmaceutical company’s stock valued at $944,000 after buying an additional 12,000 shares in the last quarter. BlackRock Inc. raised its stake in FibroGen by 1.0% in the second quarter. BlackRock Inc. now owns 6,233,136 shares of the biopharmaceutical company’s stock valued at $281,613,000 after buying an additional 60,249 shares in the last quarter. Finally, Boston Advisors LLC raised its stake in FibroGen by 61.3% in the third quarter. Boston Advisors LLC now owns 31,641 shares of the biopharmaceutical company’s stock valued at $1,170,000 after buying an additional 12,019 shares in the last quarter. Hedge funds and other institutional investors own 68.39% of the company’s stock.
In related news, SVP Christine Chung sold 5,625 shares of FibroGen stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $45.98, for a total value of $258,637.50. Following the completion of the transaction, the senior vice president now directly owns 138,269 shares in the company, valued at $6,357,608.62. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kalevi Kurkijarvi sold 6,000 shares of FibroGen stock in a transaction on Monday, December 9th. The shares were sold at an average price of $47.50, for a total value of $285,000.00. Following the completion of the transaction, the director now owns 34,400 shares of the company’s stock, valued at $1,634,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,295 shares of company stock valued at $1,721,971. Company insiders own 7.83% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Recommended Story: What is the definition of a trade war?
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.